The discovery of somatic mutations in epidermal growth receptor (EGFR) in patients who show dramatic response to reversible EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib has introduced the concept of """"""""personalized therapy in lung cancer treatment. However, resistance to the inhibitors emerges within one to two years. The secondary EGFR-T790M mutation, in the """"""""gate-keeper"""""""" position of the tyrosine kinase domain, is present in more than 50% of lung cancers with acquired resistance to gefitinib or erlotinib. Since treatment options for these patients are currently limited, novel strategies to prevent or overcome acquired resistance to EGFR TKIs are sorely needed. We have demonstrated that ?-catenin is upregulated and activated in lung cancer cells harboring EGFR mutations including EGFR-T790M. As aberrant activation of ?-catenin signaling can lead to human cancers, we hypothesize that ?-catenin plays an essential role in lung tumorigenesis caused by EGFR mutants and inhibiting its activation alone or in combination with irreversible EGFR inhibitors may be an alternative strategy to overcome resistance to gefitinib or erlotinib. Therefore, our specific aims are to: (1) Investigate the mechanisms by which EGFR mutants lead to accumulation, nuclear translocation, and activation of ?-catenin;(2) Investigate whether activation of ?-catenin is required for EGFR- T790M-driven lung cancer formation/progression in vivo;and (3) Evaluate the effectiveness of ?-catenin inhibition as a novel therapeutic strategy to overcome resistance to erlotinib or gefitinib. We believe that the experiments proposed here will provide novel insights into the detailed mechanisms by which EGFR mutations cause tumorigenesis and innovative approaches to overcome resistance to gefitinib or erlotinib, significantly impacting care of patients with lung cancer in the near future.
Lung cancer is number one cause of cancer-related deaths in the United States. Our major goal is to investigate the role of the -catenin signaling in tumors resistant to targeted therapies. A better understanding of lung tumorigenesis will lead to novel therapeutic strategies in the future.
|Lucena-Araujo, Antonio R; Moran, Jason P; VanderLaan, Paul A et al. (2016) De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naÃ¯ve ALK rearranged lung cancers. Lung Cancer 99:17-22|
|Kobayashi, Susumu S; Vali, Shireen; Kumar, Ansu et al. (2016) Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. Oncotarget 7:35989-36001|
|Costa, Daniel B; Jorge, Susan E; Moran, Jason P et al. (2016) Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol 11:918-23|
|Forloni, Matteo; Gupta, Romi; Nagarajan, Arvindhan et al. (2016) Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Rep 16:457-71|
|Costa, Daniel B; Kobayashi, Susumu S (2015) Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Transl Lung Cancer Res 4:809-15|
|Le, Xiuning; Freed, Jason A; VanderLaan, Paul A et al. (2015) Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer 16:e105-9|
|Cai, Yi; Hirata, Ayako; Nakayama, Sohei et al. (2015) CCAAT/enhancer binding protein Î² is dispensable for development of lung adenocarcinoma. PLoS One 10:e0120647|
|Jorge, Susan E; Schulman, Sol; Freed, Jason A et al. (2015) Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 90:369-74|
|Hirano, Toshiyuki; Yasuda, Hiroyuki; Tani, Tetsuo et al. (2015) In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 6:38789-803|
|Yamaguchi, Norihiro; Lucena-Araujo, Antonio R; Nakayama, Sohei et al. (2014) Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 83:37-43|
Showing the most recent 10 out of 18 publications